Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Stock data | 2023 | Change |
---|---|---|
Price | $5.96 | N/A |
Market Cap | $475.53M | N/A |
Shares Outstanding | 79.79M | 3.74% |
Employees | 40.00 | N/A |
Shareholder Equity | 141.85M | -0.45% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -9.93 | N/A |
P/B Ratio | 3.35 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.3349 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$47.51M | N/A |
EPS | -0.6 | N/A |
Earnings Yield | -0.1007 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $154.39M | N/A |
Cash on Hand | $151.02M | N/A |
Debt to Equity | 0.0884 | 23.27% |
Current Ratio | $12.32 | -17.61% |